# A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

> **NCT05162469** · PHASE1 · COMPLETED · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Advanced Malignant Cancer

## Interventions

- **DRUG:** SHR-1909 injection

## Key facts

- **NCT ID:** NCT05162469
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-23
- **Primary completion:** 2024-03-28
- **Final completion:** 2024-06-13
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162469, "A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05162469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*